Contineum Therapeutics, Inc. - 10-Q Filing
Contineum Therapeutics reports third quarter 2026 financial results including details on At-The-Market offering activity and equity incentive plans.
Tickers: $CTNM
Contineum Therapeutics reports third quarter 2026 financial results including details on At-The-Market offering activity and equity incentive plans.
Tickers: $CTNM